This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tian, K. Articles by Xu, H. Search for Related Content PubMed PubMed Citation Articles by Tian, K. Articles by Xu, H.

Epigenetic Regulation of WTH3 in Primary and Cultured Drug-Resistant Breast Cancer Cells

¹ Department of Biochemistry and Cell Biology, State University of New York at Stony Brook, Stony Brook, New York; ² North Shore-Long Island Jewish Research Institute; and ³ Department of Medicine, Division of Infectious Disease, North Shore University Hospital, Manhasset, New York

Requests for reprints: Haopeng Xu, Department of Biochemistry and Cell Biology, State University of New York at Stony Brook, R474 Life Science Building, Stony Brook, NY 11794-5215. Phone: 631-632-8566; Fax: 631-632-8575; E-mail: hduffy{at}notes.cc.sunysb.edu.

Previous studies showed that the WTH3 gene functioned as a negative regulator during multidrug resistance (MDR) development in vitro. To understand whether this gene is also involved in clinical drug resistance, hypermethylation at its promoter region observed in cultured MDR MCF7/AdrR cells was examined in primary drug-resistant breast cancer epithelial cells isolated from effusions of breast cancer patients. The results showed that this event also occurred in drug-resistant breast cancer epithelial cells and a newly induced drug-resistant cell line, MCF7/inR. Interestingly, we found that a CpG (CpG 23) that was close to the TATA-like box was constantly methylated in the WTH3 promoter of drug-resistant breast cancer epithelial and cultured MDR cells. Mutagenic study suggested that this CpG site had a functional effect on promoter activity. We also discovered that MCF7/AdrR cells treated with trichostatin A, a histone deacetylase inhibitor, exhibited higher WTH3, but lower MDR1, expression. A reverse correlation between WTH3 and MDR1 gene expression was also observed in MCF7/AdrR, and its non-MDR parental cell line, MCF7/WT. This result indicated that both DNA methylation and histone deacetylase could act in concert to inhibit WTH3 and consequently stimulate MDR1 expression. This hypothesis was supported by data obtained from introducing the WTH3 transgene into MDR cell lines, which reduced endogenous MDR1 expression. Therefore, our studies suggested that the behavior of WTH3 in primary drug-resistant breast cancer epithelial cells was similar to that in a model system where epigenetic regulation of the WTH3 gene was linked to the MDR phenotype.

This article has been cited by other articles:

				V. F. Chekhun, N. Y. Lukyanova, O. Kovalchuk, V. P. Tryndyak, and I. P. Pogribny Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets Mol. Cancer Ther., March 1, 2007; 6(3): 1089 - 1098. [Abstract] [Full Text] [PDF]

				H. Xu, J. Shan, V. Jurukovski, L. Yuan, J. Li, and K. Tian TSP50 Encodes a Testis-Specific Protease and Is Negatively Regulated by p53 Cancer Res., February 1, 2007; 67(3): 1239 - 1245. [Abstract] [Full Text] [PDF]

				R. Kitazawa and S. Kitazawa Methylation Status of a Single CpG Locus 3 Bases Upstream of TATA-Box of Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Gene Promoter Modulates Cell- and Tissue-Specific RANKL Expression and Osteoclastogenesis Mol. Endocrinol., January 1, 2007; 21(1): 148 - 158. [Abstract] [Full Text] [PDF]

				L. Ai, W.-J. Kim, T.-Y. Kim, C. R. Fields, N. A. Massoll, K. D. Robertson, and K. D. Brown Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression Cancer Res., August 15, 2006; 66(16): 7899 - 7909. [Abstract] [Full Text] [PDF]